Methylphenidate + SPD503 (Guanfacine hydrochloride)
SPD503-205
Phase 2 small_molecule completed
Quick answer
Methylphenidate + SPD503 (Guanfacine hydrochloride) for Attention Deficit Disorder With Hyperactivity is a Phase 2 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Attention Deficit Disorder With Hyperactivity
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed